PERCH : PartnERship to Contrast HPV

EU Project Title EU4H-2021-JA-02: (DP/C-g-08.1.2) Direct grant to Member States’ authorities: support to assist Member States to roll out large-scale human papillomavirus vaccination campaigns

Work Programme : EU4Health

Type of Action : PJG

Budget 4.750.000,01 €

Project duration : 01 November 2022 - 30 April 2025 (30 months)

Lead Coordinator : ISS, Italy

Contact : Be_EBCP@sciensano.be, Marc Arbyn

Website : under construction

Domain / Area : Prevention

Main objectives

The aim of this joint action is to contribute to the implementation of Europe’s Beating Cancer Plan, which aims to support Member States’ efforts to extend the roll-out of routine HPV vaccination of girls and boys to eliminate cervical cancer and other cancers caused by HPV in the coming decade.

The joint action will support the exchange of validated best practices between the Member States to ensure a consistent and efficient roll-out of HPV vaccination.

Specific Objectives:

  1. To improve evidence on how HPV vaccination and HPV screening are implemented and monitored in all participating countries
  2. To improve data and monitoring system on HPV vaccination and HPV screening
  3. To improve HPV awareness
  4. To improve knowledge and abilities for health professionals in vaccine communication

Consortium

Partners

  • 19 Countries
  • 34 partners

​Belgian partners

  • Sciensano

Structure

  • WP1 : Project Management & Coordination (Instituto Superriore di Sanita (ISS) - Italy)
  • WP2 : Dissemination (Onkoloski Institut Ljubljana (OI Ljubljana) - Slovenia)
  • WP3 : Evaluation (Institut Catala d'Oncologia (ICO) - Spain)
  • WP4 : Integration & Sustainability (Sciensano - Belgium)
  • WP5 : Monitoring (Sciensano/ICO)
  • WP6 : Improving knowledge & awareness to increase vaccin uptake in target communities (ISS/1st Ygeionomiki Perifereia Dype Attikis (1st YPE) - Greece)
  • WP7 : Training & support in vaccine communication (Bundeszentrale fur gesundheitliche Aufklarung (BZgA- - Germany)

EBCP Flagships

  • F3. Vaccinate at least 90% of girls and a significant increase of boys against human papillomaviruses by 2030 with support from EU funds and investment in infrastructure.

Actions

  • A2. Saving lives through sustainable cancer prevention

Link to Cancer Mission / recommendations

  • R3: Support the development and implementation of effective cancer prevention strategies and policies within Member States and the EU

Keywords

  • HPV
  • vaccination coverage 
  • cervical cancer

 

Autres projets

ECHoS : Establishing of Cancer Mission Hubs: Networks and Synergies

PREHDICT : Health-economic modelling of PREvention strategies for Hpv-related DIseases in European CounTries

Haute Autorité de la Santé (France) : Soutien à l'introduction du dépistage HPV

EU-TOPIA : “TOwards imProved screening for breast, cervical and colorectal cancer In All of EUrope”

Centre for Disease Control (USA) : Mises à jour des revues systématiques

CoheaHr : Comparing health services interventions for the prevention of HPV-related cancer

HPV OncoPredict (Horizon 2020)

Unité Epidémiologie Cancer HPV OncoPredict (Horizon 2020)

Triage HPV AUSTRALIA

Unité Epidémiologie Cancer Triage HPV AUSTRALIA

Healthy Cloud : Health Research & Innovation Cloud

GDI : Genomic Data Infrastructure

European Health Data Space GDI : Genomic Data Infrastructure

JANE : Joint Action on European Networks of Expertise

CanScreen-ECIS : Strengthening Cancer Screening data collection to update European Cancer Information System and improve quality and coverage of cancer screening programmes in Europe

4.UNCAN.eu : A Coordination and Support Action to prepare UNCAN.eu platform

CAN.HEAL, Building the EU Cancer and Public Health Genomics : Action grants for ‘Cancer Diagnostic and Treatment for All’ including ‘Genomic for Public Health’

BY-COVID : BeYond-COVID

eCAN : Joint Action on strengthening ehealth including telemedicine and remote monitoring for health care systems for cancer prevention and care

CRaNE : Joint Action on EU Network of Comprehensive Cancer Centres

B1MG : B1+M Genomes